Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vical plummets on placebo promise in herpes study

This article was originally published in Scrip

Executive Summary

San Diego-based Vical's stock was cut almost in half on 23 June after the company reported that the placebo in a Phase I/II clinical trial outperformed both the monovalent and bivalent forms of its therapeutic genital herpes vaccine by a wide margin. In terms of the trial's primary endpoint, viral shedding decreased 12% for patients treated with the monovalent vaccine, 19% in the study's bivalent arm and 45% in the placebo group.

You may also be interested in...



Vical Faced With Failure of Another Vaccine Trial

Company will focus on getting oral anti-fungal candidate VL-2397 over the finish line, after another pipeline blow-up.

Venture Capital Fundraising Rebounds In Q1 As Mega-Rounds Dominate

Biopharma firms raised $6bn in the first quarter of 2024, the most of any quarter since Q2 2022. But without an increase in the number of companies raising funds, the rebound remains uneven.

Pharma On The Hunt For Oncology Partners Across Modalities

The Inaugural AACR Oncology Industry Partnering Event gave pharma firms an opportunity to tell potential cancer drug collaborators what they need from external sources.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC029056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel